254 related articles for article (PubMed ID: 33766105)
21. Behavioural optimisation to address trial conduct challenges: case study in the UK-REBOA trial.
Lawrie L; Duncan EM; Jansen JO; Campbell MK; Brunsdon D; Skea Z; Coffey T; Cochran C; Gillies K
Trials; 2022 May; 23(1):398. PubMed ID: 35550599
[TBL] [Abstract][Full Text] [Related]
22. Barriers and enablers to providing evidence-based in-hospital urinary continence care: A cross-sectional survey informed by the Theoretical Domains Framework.
Boyle K; Marsden DL; Waller A; Duff J
J Clin Nurs; 2023 Aug; 32(15-16):5103-5112. PubMed ID: 37272209
[TBL] [Abstract][Full Text] [Related]
23. Stakeholder perspectives on barriers and enablers to recruiting anxious children undergoing day surgery under general anaesthetic: a qualitative internal pilot study of the MAGIC randomised controlled trial.
Kettle J; Deery C; Bolt R; Papaioannou D; Marshman Z
Trials; 2021 Jul; 22(1):458. PubMed ID: 34271982
[TBL] [Abstract][Full Text] [Related]
24. Barriers and enablers of recognition and response to deteriorating patients in the acute hospital setting: A theory-driven interview study using the Theoretical Domains Framework.
Smith D; Cartwright M; Dyson J; Hartin J; Aitken LM
J Adv Nurs; 2021 Jun; 77(6):2831-2844. PubMed ID: 33739478
[TBL] [Abstract][Full Text] [Related]
25. A qualitative study exploring perceived barriers and enablers to fidelity of training and delivery for an intervention to reduce non-indicated imaging for low back pain.
To D; De Carvalho D; Pike A; Lawrence R; Etchegary H; Patey AM; Toomey E; Hall A
Chiropr Man Therap; 2023 Jan; 31(1):6. PubMed ID: 36721165
[TBL] [Abstract][Full Text] [Related]
26. Identifying the barriers and enablers in the implementation of the New Zealand and Australian Antenatal Corticosteroid Clinical Practice Guidelines.
Mc Goldrick EL; Crawford T; Brown JA; Groom KM; Crowther CA
BMC Health Serv Res; 2016 Oct; 16(1):617. PubMed ID: 27793150
[TBL] [Abstract][Full Text] [Related]
27. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
[TBL] [Abstract][Full Text] [Related]
28. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
29. Using theories of behaviour to understand transfusion prescribing in three clinical contexts in two countries: development work for an implementation trial.
Francis JJ; Tinmouth A; Stanworth SJ; Grimshaw JM; Johnston M; Hyde C; Stockton C; Brehaut JC; Fergusson D; Eccles MP
Implement Sci; 2009 Oct; 4():70. PubMed ID: 19852832
[TBL] [Abstract][Full Text] [Related]
30. Barriers and enablers for deprescribing benzodiazepine receptor agonists in older adults: a systematic review of qualitative and quantitative studies using the theoretical domains framework.
Evrard P; Pétein C; Beuscart JB; Spinewine A
Implement Sci; 2022 Jul; 17(1):41. PubMed ID: 35804428
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
32. A cross-country comparison of intensive care physicians' beliefs about their transfusion behaviour: a qualitative study using the Theoretical Domains Framework.
Islam R; Tinmouth AT; Francis JJ; Brehaut JC; Born J; Stockton C; Stanworth SJ; Eccles MP; Cuthbertson BH; Hyde C; Grimshaw JM
Implement Sci; 2012 Sep; 7():93. PubMed ID: 22999460
[TBL] [Abstract][Full Text] [Related]
33. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
34. Barriers and enablers to physical activity in patients during hospital stay: a scoping review.
Geelen SJG; van Dijk-Huisman HC; de Bie RA; Veenhof C; Engelbert R; van der Schaaf M; Lenssen AF
Syst Rev; 2021 Nov; 10(1):293. PubMed ID: 34736531
[TBL] [Abstract][Full Text] [Related]
35. Barriers to and enablers of type 2 diabetes screening among women with prior gestational diabetes: A qualitative study applying the Theoretical Domains Framework.
Lake AJ; Williams A; Neven ACH; Boyle JA; Dunbar JA; Hendrieckx C; Morrison M; O'Reilly SL; Teede H; Speight J
Front Clin Diabetes Healthc; 2023; 4():1086186. PubMed ID: 36993822
[TBL] [Abstract][Full Text] [Related]
36. Barriers to and enablers of diabetic retinopathy screening attendance: a systematic review of published and grey literature.
Graham-Rowe E; Lorencatto F; Lawrenson JG; Burr JM; Grimshaw JM; Ivers NM; Presseau J; Vale L; Peto T; Bunce C; J Francis J
Diabet Med; 2018 Oct; 35(10):1308-1319. PubMed ID: 29790594
[TBL] [Abstract][Full Text] [Related]
37. Barriers and enablers to effective interprofessional teamwork in the operating room: A qualitative study using the Theoretical Domains Framework.
Etherington C; Burns JK; Kitto S; Brehaut JC; Britton M; Singh S; Boet S
PLoS One; 2021; 16(4):e0249576. PubMed ID: 33886580
[TBL] [Abstract][Full Text] [Related]
38. Supporting Trial Participation in People with the Huntington's Gene: A Patient-Centered, Theory-Guided Survey of Barriers and Enablers.
Carroll K; Hudek N; Bénard A; Presseau J; Richards DP; Susan M; Fergusson DA; Graham ID; Mestre TA; Brehaut JC
J Huntingtons Dis; 2022; 11(4):421-434. PubMed ID: 36155526
[TBL] [Abstract][Full Text] [Related]
39. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
40. Defining barriers and enablers for clinical pathway implementation in complex clinical settings.
Jabbour M; Newton AS; Johnson D; Curran JA
Implement Sci; 2018 Nov; 13(1):139. PubMed ID: 30419942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
